aTyr Pharma
ATYR
87 hedge funds and large institutions have $187M invested in aTyr Pharma in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 16 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 14
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
13% more funds holding
Funds holding: 77 → 87 (+10)
4.12% more ownership
Funds ownership: 65.38% → 69.5% (+4.1%)
6% less capital invested
Capital invested by funds: $199M → $187M (-$12.2M)
66% less call options, than puts
Call options by funds: $778K | Put options by funds: $2.32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$9.67M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.13M |
| 3 |
Millennium Management
New York
|
+$4.49M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.45M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.43M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.62M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.62M |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
-$1.57M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$984K |
ATYR Hedge Fund Activity: Q1 2025 in Review
87 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2025, worth a combined $187M — down 6.1% from $199M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ATYR positions and 16 closed out — a net gain of 10 holders — while 36 added to existing stakes and 14 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $9.67M. The largest seller was Point72 Asset Management, cutting an estimated $7.43M.
- 87 institutional investors held aTyr Pharma (ATYR) as of Q1 2025, up from 77 in Q4 2024.
- Funds reported $187M of aTyr Pharma stock for Q1 2025, down 6.1% quarter-over-quarter.
- 26 funds opened new aTyr Pharma positions in Q1 2025 and 16 closed out, a net change of +10 holders.
- The largest aTyr Pharma buyer in Q1 2025 was Octagon Capital Advisors, an estimated $9.67M added.
- The largest aTyr Pharma seller in Q1 2025 was Point72 Asset Management, an estimated $7.43M sold.
Based on aggregated 13F filings for Q1 2025.